Clinical Trials
16 trialsNCT06694454 2026-05-27
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT07586813 2026-05-14
N01-A-PICIT-GI
Peking University People's Hospital
Phase 2 Recruiting
NCT07586826 2026-05-14
N01-A-PICIT-GT
Peking University People's Hospital
Phase 2 Recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT06647680 2026-03-06
Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer(CONTROL-01)
The Affiliated Hospital of Qingdao University
Phase 2 Recruiting
NCT06130995 2026-03-05
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
University of Oklahoma
Phase 1 Recruiting
NCT04055220 2026-02-17
REGOSTA
Centre Leon Berard
Phase NA Recruiting
NCT07353723 2026-01-20
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
Tang-Du Hospital
Phase 2 Recruiting
NCT07353840 2026-01-20
T-START-CR
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Recruiting
NCT07328841 2026-01-09
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
Sun Yat-sen University
Phase 3 Recruiting
NCT07328854 2026-01-09
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT06364371 2025-12-18
Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Recruiting
NCT07066189 2025-10-29
Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
Yale University
Phase NA Recruiting
NCT07166185 2025-09-10
NEOTRAPSCAL
Blida 1 University
Recruiting
NCT06811844 2025-07-01
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT06927180 2025-06-23
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Henan Cancer Hospital
Phase 2 Recruiting